Moderna and Pfizer: A Tale of Two mRNA Coronavirus Vaccine Stocks
"It was the best of times, it was the worst of times..." That's how Charles Dickens' A Tale of Two Cities begins. And that describes Moderna (NASDAQ: MRNA) and Pfizer's (NYSE: PFE) situations today. The pandemic definitely makes this time one of the worst in recent memory. But against the coronavirus backdrop, some leaders in the vaccine race are experiencing their best moments.
Ten programs are currently involved in phase 3 trials. But Moderna and Pfizer are arguably the closest to earning Emergency Use Authorizations (EUAs) for their vaccine candidates. Both expect trial readouts around the end of the month, and interestingly, both players aren't developing traditional vaccines. Instead, their candidates use messenger RNA (mRNA) technology. Let's take a closer look at each company's development path so far -- and what may lie ahead.
Image source: Getty Images
Source Fool.com
